Cargando…

BMP-4 Genetic Variants and Protein Expression Are Associated with Platinum-Based Chemotherapy Response and Prognosis in NSCLC

To explore the role of genetic polymorphisms of bone morphogenic proteins 4 (BMP-4) in the response to platinum-based chemotherapy and the clinical outcome in patients with advanced nonsmall cell lung cancer (NSCLC), 938 patients with stage III (A+B) or IV NSCLC were enrolled in this study. We found...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xian, Sun, Jilu, Lang, Zhennan, Tian, Yang, Zhou, Yang, Hu, Jingshu, Geng, Songbin, Fu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3977566/ https://www.ncbi.nlm.nih.gov/pubmed/24779016 http://dx.doi.org/10.1155/2014/801640

Ejemplares similares

Polymorphisms of CCNB1 Associated With the Clinical Outcomes of Platinum-Based Chemotherapy in Chinese NSCLC Patients
por: Liu, Di, et al.
Publicado: (2017)

Genetic Variants in DNA Mismatch Repair Pathway predict prognosis of Lung Cancer patients with receiving Platinum-Based Chemotherapy
por: Liu, Jun-Yan, et al.
Publicado: (2020)

IMpower132: Atezolizumab plus platinum‐based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients
por: Nishio, Makoto, et al.
Publicado: (2021)

Association between Genetic Variants and Peripheral Neuropathy in Patients with NSCLC Treated with First-Line Platinum-Based Therapy
por: de Jong, Corine, et al.
Publicado: (2023)

Influence of Programmed Death Ligand-1-Gene Polymorphism rs822336 on the Prognosis and Safety of Postoperative Patients with NSCLC Who Received Platinum-Based Adjuvant Chemotherapy
por: Zhao, Ming, et al.
Publicado: (2020)

Genetic Variants in Double-Strand Break Repair Pathway Genes to Predict Platinum-Based Chemotherapy Prognosis in Patients With Lung Cancer
por: Liu, Jun-Yan, et al.
Publicado: (2022)

RAGE Genetic Polymorphisms Are Associated with Risk, Chemotherapy Response and Prognosis in Patients with Advanced NSCLC
por: Wang, Xiang, et al.
Publicado: (2012)

A miR‐15a related polymorphism affects NSCLC prognosis via altering ERCC1 repair to platinum‐based chemotherapy
por: Xue, Ping, et al.
Publicado: (2022)

Clinical Trial and Real-World Outcomes of Patients With Metastatic NSCLC in the Post-Platinum–Based Chemotherapy Failure Setting
por: Soon, Yu Yang, et al.
Publicado: (2023)

Pharmacogenomics of platinum-based chemotherapy response in NSCLC: a genotyping study and a pooled analysis
por: Chen, Juan, et al.
Publicado: (2016)

RAD52 Variants Predict Platinum Resistance and Prognosis of Cervical Cancer
por: Shi, Ting-Yan, et al.
Publicado: (2012)

ZNF76 predicts prognosis and response to platinum chemotherapy in human ovarian cancer
por: Hua, Tian, et al.
Publicado: (2021)

Poor response to platinum-based chemotherapy is associated with KRAS mutation and concomitant low expression of BRAC1 and TYMS in NSCLC
por: Zhou, Hongxuan, et al.
Publicado: (2016)

Meta-Analysis on Pharmacogenetics of Platinum-Based Chemotherapy in Non Small Cell Lung Cancer (NSCLC) Patients
por: Yin, Ji-Ye, et al.
Publicado: (2012)

Prognostic significance of galectin‐3 expression in patients with resected NSCLC treated with platinum‐based adjuvant chemotherapy
por: Kusuhara, Seiichiro, et al.
Publicado: (2021)

OPN Polymorphism Is Related to the Chemotherapy Response and Prognosis in Advanced NSCLC
por: Hao, Yanzhang, et al.
Publicado: (2014)

Pharmacogenetic Association between XRCC1 Polymorphisms and Response to Platinum-Based Chemotherapy in Asian Patients with NSCLC: A Meta-Analysis
por: Zhang, Ningning, et al.
Publicado: (2020)

The Association Between Genetic Polymorphisms of Transporter Genes and Prognosis of Platinum-Based Chemotherapy in Lung Cancer Patients
por: He, Jia, et al.
Publicado: (2022)

Genetic Polymorphisms and the Efficacy of Platinum-Based Chemotherapy: Review
por: Afifah, Nadiya Nurul, et al.
Publicado: (2020)

Aberrant Promoter Methylation of Caveolin-1 Is Associated with Favorable Response to Taxane-Platinum Combination Chemotherapy in Advanced NSCLC
por: Brodie, Seth A., et al.
Publicado: (2014)

Meta-Analysis of Therapy of Cinobufacini Capsule Adjunct with First-Line Platinum-Based Chemotherapy for the Treatment of Advanced NSCLC
por: Peng, Wenpan, et al.
Publicado: (2021)

Breast cancer susceptibility gene 1 (BRCA1) predict clinical outcome in platinum- and toxal-based chemotherapy in non-small-cell lung cancer (NSCLC) patients: a system review and meta-analysis
por: Yang, Yanlong, et al.
Publicado: (2013)

Predicting the Role of DNA Polymerase β Alone or with KRAS Mutations in Advanced NSCLC Patients Receiving Platinum-Based Chemotherapy
por: Alvisi, Maria Francesca, et al.
Publicado: (2020)

Establishing a Prediction Model for the Efficacy of Platinum—Based Chemotherapy in NSCLC Based on a Two Cohorts GWAS Study
por: Xiao, Qi, et al.
Publicado: (2023)

Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy
por: Hayashi, Hidetoshi, et al.
Publicado: (2023)

Association of variations in the CAT and prognosis in lung cancer patients with platinum-based chemotherapy
por: Liu, Jia-Si, et al.
Publicado: (2023)

Nimotuzumab plus platinum-based chemotherapy versus platinum-based chemotherapy alone in patients with recurrent or metastatic nasopharyngeal carcinoma
por: Zhu, Yunshu, et al.
Publicado: (2020)

SIRT1 Expression Is Associated with the Chemotherapy Response and Prognosis of Patients with Advanced NSCLC
por: Zhang, Tao, et al.
Publicado: (2013)

SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting
por: Greystoke, Alastair, et al.
Publicado: (2017)

The Influence of KDR Genetic Variation on the Efficacy and Safety of Patients With Advanced NSCLC Receiving First-Line Bevacizumab Plus Chemotherapy Regimen
por: Geng, Nan, et al.
Publicado: (2021)

Sequential Whole Exome Sequencing Reveals Somatic Mutations Associated with Platinum Response in NSCLC
por: Guo, Ao-Xiang, et al.
Publicado: (2020)

Screening-based approach to discover effective platinum-based chemotherapies for cancers with poor prognosis
por: Varbanov, Hristo P., et al.
Publicado: (2019)

The Effects of WISP1 Polymorphisms on the Prognosis of Lung Cancer Patients with Platinum-Based Chemotherapy
por: He, Jia, et al.
Publicado: (2021)

Metabolites as Prognostic Markers for Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Platinum-Doublet Chemotherapy
por: Hao, Desirée, et al.
Publicado: (2020)

Deconstructing ADAURA. It is Not Yet Time to Forgo Platinum-based Adjuvant Chemotherapy in Resected Early Stage (IB-IIIA) EGFR-mutant NSCLC
por: Brazel, Danielle, et al.
Publicado: (2022)

Implication of VEGFR2 Polymorphism on the Prognosis of Anlotinib Monotherapy for Patients With Treatment-Refractory Advanced NSCLC: An Exploratory Study
por: Li, Xiaoyuan, et al.
Publicado: (2022)

The efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC)
por: Yang, Jiaying, et al.
Publicado: (2016)

Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the EAST-LC Trial
por: Yang, James Chih-Hsin, et al.
Publicado: (2021)

Bevacizumab in Combination with Pemetrexed and Platinum Significantly Improved the Clinical Outcome of Patients with Advanced Adenocarcinoma NSCLC and Brain Metastases
por: Tian, Yaru, et al.
Publicado: (2019)

Primary malignant mediastinal germ cell tumours: improved prognosis with platinum-based chemotherapy and surgery.
por: Childs, W. J., et al.
Publicado: (1993)

Cannot write session to /tmp/vufind_sessions/sess_41td23cn3ckl6bckn5eu5e0tns